GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
J

JRsis Health Care JRSS · USD

N/A · US listing · 🇺🇸 United States

Compare

0.01

—

Close of 30 Oct 2026, in USD

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$320,212

FY2016FY2025

Net income

$8,816

FY2016FY2025

Free cash flow

−$135,552

FY2016FY2025

Shareholders' equity

−$188,888

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$320,212$1.3m$3.5m$44.4m$35.7m$31.5m$28.4m$24.1m$18.1m
Research and development$9,442$49,693$189,266——————
Operating income$8,171−$486,000−$188,598$4.1m$5.6m$4.7m$6.0m$6.7m$5.0m
Net income$8,816−$509,790−$80,912$2.2m$2.7m$888,061$2.0m$4.6m$3.5m
Diluted earnings per share0.00-0.01-0.000.120.150.050.040.240.21

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$431,617$1.2m$2.1m$75.7m$58.8m$51.6m$52.5m$48.7m$31.7m
Cash and short-term investments$30,066$108,515$118,114$855,971$844,827$2.0m$256,450$884,292$890,662
Total liabilities$653,972$1.5m$2.3m$42.6m$30.0m$28.6m$30.4m$28.4m$20.0m
Debt——$1.0m$24.3m$18.5m$19.7m$24.9m$28.4m$19.1m
Shareholders' equity−$188,888−$197,704−$137,406$22.1m$19.0m$14.8m$14.1m$12.9m$6.6m
Shares outstanding85m85m83m19m18m18m53m20m17m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−$135,551−$438,313$516,724$8.2m$10.6m$11.8m$9.2m$8.3m$5.0m
Capital spending−$1−$3−$1,484−$5.5m−$8.3m−$4.0m−$6.0m−$13.5m−$3.6m
Free cash flow−$135,552−$438,316$515,240$2.7m$2.4m$7.9m$3.2m−$5.2m$1.4m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$58,140$54,348$56,818$56,497$68,966$137,931$4,125$222,922
Operating income$2,450−$4,160−$3,538−$3,669−$1,328$16,706−$186−$206,190
Net income$2,607−$4,008−$3,370−$3,501−$1,207$16,894−$110−$188,146
Diluted earnings per share0.00-0.00-0.00-0.00-0.000.00-0.00-0.00
Total assets$322,130$394,863$431,617$537,363$735,057$1.0m$1.2m$2.1m
Cash and short-term investments$37,957$54,368$30,066$55,387$84,474$105,404$108,515$1,372
Debt———$50,000———$1.4m
Shareholders' equity−$106,289−$192,896−$188,888−$183,223−$182,017−$180,810−$197,704−$197,594

Growth per year

Compound annual rate

3 years5 years10 years
Revenue53.1%-61.0%-30.3%
Operating income—-72.9%-43.9%
Net income—-68.1%-41.2%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-29.0%-19.1%10.2%16.9%
Net margin-30.5%-660.2%-34.5%-8.3%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022
Price to earnings18.3-0.1-0.3—
Price to sales0.50.10.00.0

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return105%204%3682%32%1862%313%162%53%129%21%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 10-to-1 reverse split · 30 Jun 2023
  • 6-for-5 split · 10 May 2019

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.